AgeX Therapeutics to Present at Biotech Showcase 2019
January 02 2019 - 7:00AM
Business Wire
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology
company focused on developing and commercializing innovative
therapeutics for human aging, today announced that it will present
at Biotech Showcase, to be held January 7-9, 2019 in San
Francisco, California.
AgeX Founder and CEO Michael D. West, Ph.D., will be speaking at
the conference as follows:
Date: Wednesday, January 9Time: 9:00AM
PSTTrack: Yosemite-A (Ballroom
Level)Venue: Hilton San Francisco Union Square, 333
O’Farrell Street, San Francisco, Calif.
According to the event organizers, Biotech Showcase features
more than 3,500 decision makers from 2,100 life sciences companies
in a variety of plenary sessions, fireside chats, and panels.
Additional information and registration may be found here.
To schedule a meeting with Dr. West during Biotech Showcase,
please write to bill@gothamcomm.com.
A copy of Dr. West’s presentation will be available on the
AgeX website.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is aggressively developing
its core product pipeline toward the clinic to extend human
healthspan and seeking opportunities to form licensing and
partnership agreements around its broad IP estate and proprietary
technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, Facebook and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s Information Statement filed as an exhibit to its
Registration Statement on Form 10 with the Securities and Exchange
Commissions (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date
of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190102005229/en/
for AgeX:Bill DouglassGotham Communications,
LLCbill@gothamcomm.com(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024